{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:27:45Z","timestamp":1786440465143,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007460","name":"Arvid Nilsson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002918","name":"Gentofte Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006426","name":"Eva and Henry Fr\u00e6nkel Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010306","name":"Director Kurt B\u00f8nnelycke and Wife Mrs Grethe B\u00f8nnelyckes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009584","name":"The Toyota Foundation","doi-asserted-by":"publisher","award":["KJ\/BG-9981 H"],"award-info":[{"award-number":["KJ\/BG-9981 H"]}],"id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010358","name":"KV Fonden","doi-asserted-by":"publisher","award":["2021-0703"],"award-info":[{"award-number":["2021-0703"]}],"id":[{"id":"10.13039\/501100010358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Heart Foundation","doi-asserted-by":"publisher","award":["20-R142-A9780-22179"],"award-info":[{"award-number":["20-R142-A9780-22179"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cardfail.2026.01.025","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:04:54Z","timestamp":1773335094000},"page":"1396-1407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-5736","authenticated-orcid":false,"given":"JULIE HEMPEL","family":"LARSEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAMILLA FUCHS","family":"ANDERSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIA CALLESEN","family":"HANSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASSAR","family":"OMAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JESPER","family":"JENSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LISBETH","family":"ANTONSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PER LAV","family":"MADSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JULIE LYNG","family":"FORMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KURT","family":"H\u00d8JLUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FILIP KRAG","family":"KNOP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MIKAEL KJ\u00c6R","family":"POULSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MORTEN","family":"SCHOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-5845","authenticated-orcid":false,"given":"JACOB EIFER","family":"M\u00d8LLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cardfail.2026.01.025_bib0001","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.cardfail.2026.01.025_bib0002","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure","volume":"171","author":"Cook","year":"2014","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.cardfail.2026.01.025_bib0003","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1253\/circj.CJ-16-0062","article-title":"From left ventricular hypertrophy to dysfunction and failure","volume":"80","author":"Lazzeroni","year":"2016","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.cardfail.2026.01.025_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1148\/radiol.2019182871","article-title":"Left ventricular mass at MRI and long-term risk of cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"293","author":"Kawel-Boehm","year":"2019","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.cardfail.2026.01.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14627","article-title":"Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study","volume":"38","author":"\u00d6zbek","year":"2021","journal-title":"Diabet Med"},{"issue":"10254","key":"10.1016\/j.cardfail.2026.01.025_bib0006","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.cardfail.2026.01.025_bib0007","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved Trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cardfail.2026.01.025_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.cardfail.2026.01.025_bib0009","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cardfail.2026.01.025_bib0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.cardfail.2026.01.025_bib0011","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF Randomized Clinical Trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.cardfail.2026.01.025_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.cardfail.2026.01.025_bib0013","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM Study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.cardfail.2026.01.025_bib0014","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10554-021-02443-5","article-title":"Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial","volume":"38","author":"Ersb\u00f8ll","year":"2022","journal-title":"Int J Cardiovasc Imaging"},{"issue":"21","key":"10.1016\/j.cardfail.2026.01.025_bib0015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.025_bib0016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ahj.2024.02.005","article-title":"Empagliflozin to elderly and obese patients with increased risk of developing heart failure: study protocol for the Empire Prevent trial program","volume":"271","author":"Andersen","year":"2024","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.cardfail.2026.01.025_bib0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2013a new world-wide definition. a consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.cardfail.2026.01.025_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","article-title":"Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing","volume":"22","author":"Schulz-Menger","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"6","key":"10.1016\/j.cardfail.2026.01.025_bib0019","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1067\/j.cpradiol.2019.09.005","article-title":"Left ventricular hypertrophy: evaluation with cardiac MRI","volume":"49","author":"Grajewski","year":"2020","journal-title":"Curr Probl Diagn Radiol"},{"issue":"11","key":"10.1016\/j.cardfail.2026.01.025_bib0020","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.025_bib0022","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF Randomized Clinical Trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.cardfail.2026.01.025_bib0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cardfail.2026.01.025_bib0024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1161\/CIRCULATIONAHA.122.062769","article-title":"Empagliflozin and left ventricular remodeling in people without diabetes: primary results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial","volume":"147","author":"Connelly","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cardfail.2026.01.025_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12933-023-01849-w","article-title":"Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin","volume":"22","author":"Puar","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.cardfail.2026.01.025_bib0026","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcmg.2009.10.012","article-title":"The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"3","author":"Turkbey","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"issue":"19","key":"10.1016\/j.cardfail.2026.01.025_bib0027","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","article-title":"Prognostic significance of left ventricular mass change during treatment of hypertension","volume":"292","author":"Devereux","year":"2004","journal-title":"JAMA"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:31Z","timestamp":1786437031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1071916426001338"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.025","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}